,12 Several preclinical and clinical studies have also demonstrated beneficial metabolic effects of PDE-5 inhibitors for manifestations of the metabolic syndrome.13, 14, 15, 16 However, no study with a pre-registered metabolic outcome has examined the effects of PDE-5 inhibition in recently diagnosed well-controlled patients with T2D of both sexes. The gene discussed is PDE5A; the disease is metabolic syndrome.